Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $4.96 Million - $6.04 Million
30,300 Added 16.49%
214,000 $42.3 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $2.43 Million - $2.84 Million
15,700 Added 9.35%
183,700 $31.5 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $16.9 Million - $19.2 Million
-105,500 Reduced 38.57%
168,000 $30.6 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $1.79 Million - $2.01 Million
13,000 Added 4.99%
273,500 $42.4 Million
Q3 2023

Nov 15, 2023

BUY
$133.59 - $154.65 $34.8 Million - $40.3 Million
260,500 New
260,500 $38.8 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $304B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.